Scientific Publications-Archives-Malaria

2004

Efficacy of therapeutic combinations with artemisinin derivatives in the treatment of non complicated malaria in Burundi by Ndayiragije A, Niyungeko D, Karenzo J, Niyungeko E, Barutwanayo M, Ciza A, Bosman A, Moyou-Somo R, Nahimana A, Nyarushatsi JP, Barihuta T, Mizero L, Ndaruhutse J, Delacollette C, Ringwald P, Kamana J. Trop Med Int Health. 2004 Jun; 9(6): 673-9.
Faced with the problem of resistance to chloroquine and sulfadoxine-pyrimethamine, the Ministry of Public Health of Burundi decided to study the efficacy of two artemisinin-based combinations, the fixed combination of artemether-lumefantrine and the combination of amodiaquine + artesunate. During a consensus workshop, the Ministry of Public Health agreed on the combination of artesunate and amodiaquine as the first line drug for the treatment of uncomplicated falciparum malaria in Burundi including epidemic outbreak.
Click here to download the full article [PDF]

Combined antimalarial therapy using artemisinin by Majori G. Parassitologia. 2004 Jun;46(1-2):85-7.
The existing armamentarium of drugs for the treatment and prevention of malaria is limited primarily by resistance (and cross-resistance between closely related drugs). However, most of these drugs still have a place and their life-span could be prolonged if better deployed and used, and also by rationally combining them based on pharmacodynamic and pharmacokinetic properties. Newer compounds are also being developed. The nature of malaria disease and its prevalence in the developing world call for innovative approaches to develop new affordable drugs and to safeguard the available ones.
Click here to access the full article

Developing artemisinin based drug combinations for the treatment of drug resistant falciparum malaria: A review by Olliaro PL, Taylor WR. J Postgrad Med. 2004 Jan-Mar; 50(1):40-4. Review.
The emergence and spread of drug resistant malaria represents a considerable challenge to controlling malaria. To date, malaria control has relied heavily on a comparatively small number of chemically related drugs, belonging to either the quinoline or the antifolate groups. Controlling resistance is key to ensuring that the investment put into developing new antimalarial drugs is not wasted. This review will summarise current antimalarial drug developments and outline recent clinical research that aims to bring artemisinin-based combinations to those that need them most.
Click here to download the full article [PDF]


2003

Antimalarial compounds: from bench to bedside by Olliaro PL, Taylor WR. J Exp Biol. 2003 Nov;206(Pt 21):3753-9.
The emergence and spread of drug-resistant malaria parasites is the major threat to effective malaria control. Experience has shown that resistance eventually curtails the life span of antimalarial drugs. If measures are not applied to contain resistance, the investment put into the development of new drugs will be squandered. This review will summarise current antimalarial drug developments and outline recent clinical research that aims to bring artemisinin-based combinations to those that need them most.
Click here to download the full article [PDF]


1999

Antiparasitic agents: challenges of sleeping sickness, hopes for malaria by Croft SL. Curr Opin Infect Dis. 1999 Dec; 12(6):557-8.
Click here to access the full article